Neurocrine announced positive topline data for its Phase 2 SAVITRI study. This dose-finding study assessed the efficacy and safety of NBI-1065845 in adult subjects with major depressive disorder – MDD -. The study met its primary and key secondary endpoints, demonstrating that once-daily, oral administration of NBI-1065845 produced a statistically significant change from baseline in MADRS total score at both Day 28 and Day 56. NBI-1065845 was generally well tolerated. The most common adverse event was headache. The adverse event profile for both doses of NBI-1065845 were comparable to placebo. There were no deaths or serious adverse events. The discontinuation rates were low throughout the study. The company expects to meet with the FDA to discuss a path into Phase 3 studies.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NBIX:
- Neurocrine, Sentia Medical Sciences extend CRF research collaboration
- Voyager announces selection of development candidate for GBA1 Program
- Neurocrine initiates Phase 1 study of NBI-1065890
- Neurocrine price target raised to $158 from $148 at JPMorgan
- Spruce Biosciences downgraded to Market Perform from Outperform at Leerink